- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01048307
Effect of Prontosan Wound Irrigation Solution on Venous Ulcers
Randomised, Controlled, Clinical Trial on the Safety and Efficacy of Prontosan Wound Irrigation Solution Compared to Standard Therapy in the Treatment of Hard-to-Heal Venous Leg Ulcers
Objective:
To evaluate the efficacy and safety of Prontosan® Wound Irrigation Solution in the treatment of hard-to-heal venous leg ulcers compared to wound irrigation with saline solution
Methodology:
Randomised, controlled multi-centre, prospective clinical trial
Planned number of subjects:
20 patients in experimental group (Prontosan® Wound Irrigation Solution) 8 patients in control group (wound irrigation with saline)
Products under investigation:
Prontosan® Wound Irrigation Solution
Study Duration:
3-4 weeks
Study Overview
Status
Intervention / Treatment
Detailed Description
Investigational product, dose and administration:
Prontosan® Wound Irrigation Solution (experimental group) and saline solution (control group) will be applied at inclusion and reapplied after dressing changes.
The treatment scheme is as follows:
Prontosan® Wound Irrigation Solution (experimental group):
- cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the immediate wound in the form of a moist compress and removed after approximately 15 minutes;
- placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;
- fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
Saline (control group):
- cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;
- placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;
- fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
Dressings will be changed and the treatment procedure will be repeated in the clinic 2x/weekly or more. The efficacy of the treatment procedure will be evaluated on the basis of a 2 week observation period.
Treatment efficacy assessment:
- Assessment of clinical signs and symptoms at entry to the study and after one and two weeks.
- Quantitative and qualitative microbiological analysis at entry to the study and after two weeks.
- Wound planimetry using PictZar® CDM at entry to the study and after two weeks.
Primary aim:
clinical signs assessed by:
- reduction of slough and necrotic tissue
- control of exudate
- presence of granulation tissue
- reduction of inflammatory signs (surrounding skin)
- reduction in wound size (assessed by wound planimetry)
- reduction of bacterial load (quantitative and qualitative microbiological
Secondary aim:
- tolerance and safety assessment:
- adverse drug reaction
- adverse events
- early withdrawal from the study
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States, 10461
- Calvary Hospital Center for Curative and Palliative Wound Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- males and females aged at least 18 with wounds of venous aetiology (documented by targeted exams) located in the lower limbs
- Ankle Brachial Index (ABI) ≥ 0.7
- patients who have not had an antimicrobial (systemic antibiotic or topical antiseptic) over the 30 days before joining the study
Exclusion Criteria:
Exclusion criteria
- age below 18 years
- presence of clinical infection, or current use of antiseptics or antibiotics
- chronic wounds of long duration (>30cm2 and >1 year duration)
- involvement in other wound related trials within the past 30 days
- sensitivity to any of the components of Prontosan® or dressing material
- intolerance to compression therapy
- active osteomyelitis in the ulceration area
- active rheumatoid arthritis (RA) requiring any immunosuppressive therapy
- collagen vascular disease active treated with steroids
- chronic diseases that could impact the course of the study (malicious cancer, TB, AIDS, mental illnesses)
- plasma protein below 4 g/dl
- anaemia: haemoglobin below 10 g/dl
- both, controlled and uncontrolled diabetics (type 1 or 2)
- patients on any rheological agents (not including aspirin)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prontosan wound irrigation solution
Prontosan® Wound Irrigation Solution (experimental group):
|
Prontosan® Wound Irrigation Solution (experimental group): • Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound Saline (control group):
Other Names:
|
Placebo Comparator: Saline irrigation (standard care control)
Saline (control group):
|
Prontosan® Wound Irrigation Solution (experimental group): • Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound Saline (control group):
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction of bacterial burden (quantitative bacteriology) Reduction in slough and necrotic tissue (clinical score) Amount and quality of granulation tissue (clinical score) Exudate type and amount (clinical score)
Time Frame: weekly
|
weekly
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse device effect (s) Adverse events
Time Frame: volunteered at any time or during weekly evaluation visits
|
volunteered at any time or during weekly evaluation visits
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Oscar M Alvarez, PhD, Calvary Hospital, Wound Care
- Study Director: Martin Wendelken, RN, DPM, Calvary Hospital, Wound Care
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Leg Ulcer
- Skin Ulcer
- Varicose Veins
- Ulcer
- Wounds and Injuries
- Varicose Ulcer
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antimetabolites
- Gastrointestinal Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Disinfectants
- Lipotropic Agents
- Pharmaceutical Solutions
- Betaine
- Polihexanide
Other Study ID Numbers
- OPM-I-H-0902
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wound Care
-
Rhode Island HospitalCompleted
-
BSN Medical Ltd. UKTerminatedWound - in Medical CareUnited Kingdom
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Enrolling by invitationWounds and Injuries | Virtual Reality | Music Therapy | Wound Care | Wound SurgicalNetherlands
-
St. James's Hospital, IrelandUnknownWound Infection; Wounds; Dehisence; Cosmesis; Home Care; Length of Hospital StayIreland
-
University of ArkansasArkansas Children's Hospital Research Institute; Arkansas Biosciences Institute and other collaboratorsTerminatedPain | Burns | Wound CareUnited States
-
Rutgers, The State University of New JerseyCompletedSurgical Wound Infection | Preoperative Care | Methicillin-Resistant Staphylococcus AureusUnited States
-
Associazione Infermieristica per lo studio delle...B. Braun Medical SACompletedPressure Ulcer | Wound Cleansing | Chronic Wound CareItaly
-
University of TorontoOntario Ministry of Health and Long Term Care; Canadian Patient Safety Institute and other collaboratorsCompletedPressure Ulcers | Multi-disciplinary Wound Care Teams | Remote Support | Digital Wound PhotographyCanada
-
Joshua ChooIntegra LifeSciences CorporationRecruitingSurgical Wound | Pressure Ulcer | Venous Ulcer | Wound Care | Trauma Wounds | Draining WoundUnited States
-
University of California, San FranciscoCompletedNausea | Vomiting | Hallucinations | Hyperalgesia | Pain Intensity | Wound CareUnited States, Puerto Rico
Clinical Trials on Prontosan wound irrigation solution
-
B. Braun Medical Inc.TerminatedWound of Lower Leg (Physical Finding)United States
-
B. Braun Ltd. Centre of Excellence Infection ControlCompletedVenous Leg UlcerUnited Kingdom
-
The First Hospital of Jilin UniversityFujian Medical University Union Hospital; Shenzhen Second People's HospitalRecruitingBurns | Diabetic Foot Ulcer | Chronic Wound | Pressure Injury | Irrigation SolutionChina
-
Associazione Infermieristica per lo studio delle...B. Braun Medical SACompletedPressure Ulcer | Wound Cleansing | Chronic Wound CareItaly
-
Georgetown UniversityCompletedWound InfectionUnited States
-
Wake Forest University Health SciencesRecruitingSpinal Cord Injuries | Pressure InjuriesUnited States
-
SoftOx Solutions ASUnknown
-
Hillel Yaffe Medical CenterUnknownWounds and InjuriesIsrael
-
Prince of Wales Hospital, Shatin, Hong KongChinese University of Hong KongCompletedAcute and Chronic WoundsChina
-
Sunnybrook Health Sciences CentreRecruitingSurgical Site InfectionCanada